

## DPPA5 Supports Pluripotency and Reprogramming by Regulating NANOG Turnover

XU QIAN,<sup>a,b</sup> JIN KOO KIM,<sup>a,b</sup> WILBUR TONG,<sup>a,b</sup> LUIS G. VILLA-DIAZ,<sup>a,b</sup> PAUL H. KREBSBACH<sup>a,b,c</sup>

**Key Words.** Embryonic stem cells • Induced pluripotent stem cells • DPPA5 • NANOG • Cell reprogramming • Self-renewal • Pluripotency

<sup>a</sup>Department of Biologic and Materials Sciences, University of Michigan School of Dentistry, Ann Arbor, Michigan, USA; <sup>b</sup>Biointerfaces Institute and <sup>c</sup>Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA

Correspondence: Paul H. Krebsbach, D.D.S., Ph.D., 1011 N. University, Room K 1030, Ann Arbor, Michigan 48109-1078, USA.  
Telephone: + 1-734-763-5280;  
Fax: + 1-734-763-3453;  
e-mail: paulk@umich.edu

Received February 12, 2015;  
accepted for publication  
October 18, 2015; first  
published online in *STEM CELLS  
EXPRESS* December 13, 2015.

© AlphaMed Press  
1066-5099/2015/\$30.00/0

[http://dx.doi.org/  
10.1002/stem.2252](http://dx.doi.org/10.1002/stem.2252)

### ABSTRACT

Although a specific group of transcription factors such as OCT4, SOX2, and NANOG are known to play essential roles in pluripotent stem cell (PSC) self-renewal, pluripotency, and reprogramming, other factors and the key signaling pathways regulating these important properties are not completely understood. Here, we demonstrate that the PSC marker Developmental Pluripotency Associated 5 (DPPA5) plays an important role in human PSC (hPSC) self-renewal and cell reprogramming in feeder-free conditions. Compared to hPSCs grown on mouse embryonic fibroblasts, cells cultured on feeder-free substrates, such as Matrigel, Laminin-511, Vitronectin, or the synthetic polymer poly[2-(methacryloyloxy) ethyl dimethyl-(3-sulfopropyl) ammonium hydroxide], had significantly higher DPPA5 gene expression and protein levels. Overexpression of DPPA5 in hPSCs increased NANOG protein levels via a post-transcriptional mechanism. Coimmunoprecipitation, protein stability assays, and quantitative RT-PCR, demonstrated that DPPA5 directly interacted, stabilized, and enhanced the function of NANOG in hPSCs. Additionally, DPPA5 increased the reprogramming efficiency of human somatic cells to induced pluripotent stem cells (hiPSCs). Our study provides new insight into the function of DPPA5 and NANOG regulation in hPSCs. *STEM CELLS* 2016;34:588–600

### SIGNIFICANCE STATEMENT

We demonstrate that the pluripotent stem cell (PSC) marker Developmental Pluripotency Associated 5 (DPPA5) stabilizes NANOG and supports human PSC (hPSC) self-renewal and cell reprogramming in feeder free conditions. This study provides new molecular insight into the function of DPPA5 in hPSCs. It extends our understanding of the mechanism by which PMEDSAH and other feeder-free conditions support hPSC self-renewal. Our findings advance our knowledge of hPSC biology, offer improvements to current protocols in hPSC maintenance and reprogramming, which may contribute to the future application of these cells in regenerative medicine.

### INTRODUCTION

Human pluripotent stem cells (hPSCs), which include embryonic stem cells (hESCs) derived from the inner cell mass of blastocyst-stage embryos, and induced pluripotent stem cells (hiPSCs) generated by reprogramming somatic cells through overexpression of key transcription factors [1–3], are promising resources for regenerative medicine. An improved understanding of these pluripotent cells may also provide insight into early human embryonic development because these cells are able to differentiate into specialized cell types of all three germ layers and trophoctoderm. A key to unlocking this stem cell potential is by advanced understanding of the molecular mechanisms governing hPSC self-renewal and the network of factors that enable pluripotency. Although it is known that

an assembly of transcription factors, including OCT4, SOX2, and NANOG, play important roles in hPSC self-renewal and pluripotency [4–7], the crucial signaling pathways and factors regulating these transcription factors is not completely understood.

The *Developmental Pluripotency Associated 5 (DPPA5)* gene, also designated *ESG1*, belongs to the *KHDC1/DPPA5/ECAT1/OOEP* gene family. These genes encode structurally related proteins characterized by an atypical RNA-binding K Homology (KH) domain and are specifically expressed in mammalian oocytes and ESCs [8]. Because of its high expression in PSC, DPPA5 has been used as an informative marker for pluripotency and stemness [9–14]. However, there is limited information regarding the function of DPPA5 in mouse or human ESCs [15].

The homeobox transcription factor NANOG has been proposed as a gatekeeper of pluripotency in hPSCs. Studies indicate that downregulation of NANOG in hESCs induces differentiation [6], while overexpression of NANOG prevents neuroectoderm differentiation and blocks progression along endodermal and mesodermal lineages [16–18]. In methods to reprogram somatic cells into iPSCs, the addition of NANOG to the *OCT4*, *SOX2*, *KLF4*, and *C-MYC* (OSKM) reprogramming cocktail enhances reprogramming kinetics [19]. Likewise, hiPSCs have been generated by the overexpression of NANOG in cooperation with the expression of *OCT4*, *SOX2*, and *LIN28* [3].

Here, we used DPPA5 as a PSC marker to investigate the mechanism by which synthetic polymer coatings such as poly[2-(methacryloyloxy) ethyl dimethyl-(3-sulfopropyl) ammonium hydroxide] (PMEDSAH) support hPSC self-renewal in feeder-free conditions [20, 21]. Our data revealed higher expression of DPPA5 in hPSCs cultured on PMEDSAH compared to irradiated mouse embryonic fibroblasts (MEFs), the most widely used culture condition [22]. This finding led us to raise the hypothesis that DPPA5 has a unique role in hPSCs self-renewal when cultured on synthetic substrates.

We first compared gene expression and protein levels of DPPA5 in hPSCs cultured on MEFs and several feeder-free conditions. In response to *DPPA5* overexpression, NANOG protein levels were stabilized. Because of the central role of NANOG in hPSC pluripotency, we investigated the mechanism by which DPPA5 regulates NANOG and the effects of DPPA5 on NANOG target genes in hESCs. We also studied the function of DPPA5 in the derivation of hiPSCs and found *DPPA5* enhanced the reprogramming efficiency when combined with *OCT4*, *SOX2*, *KLF4*, and *C-MYC*.

## MATERIALS AND METHODS

### Cell Culture Substrates Preparation

All cell culture was performed in designated incubators at 37°C in 5% CO<sub>2</sub>, and high humidity. irradiated MEFs (MTI-GlobalStem, Gaithersburg, MD, <http://www.mti-globalstem.com>) were plated at a density of  $2 \times 10^4$  cells per centimeter square on gelatin-coated tissue culture dishes. The fibroblast culture medium was composed of high-glucose Dulbecco's modified Eagle's medium (DMEM) (Gibco, Grand Island, NY, <http://www.invitrogen.com>), 10% fetal bovine serum (FBS; Gibco), 1% non-essential amino acids (Gibco), 1% GlutaMax (Gibco), and 1% penicillin streptomycin (Gibco).

The synthetic surface PMEDSAH was prepared as described previously [23]. Briefly, through ultraviolet ozone (UVO)-initiated free radical polymerization in a fume hood with connections for argon, a 500 ml reaction vessel was degassed by vacuum for 1 hour. When the reaction vessel was being evacuated, a monomer solution consisting of 0.25 M MEDSAH (Sigma-Aldrich, St. Louis, <http://www.sigmaaldrich.com>) was dissolved in a mixture of deionized water and ethanol (4:1, v/v). The solution was degassed for 40 minutes with an argon purge. After the reaction vessel and solvent were degassed, the monomer solution was transferred to a reaction vessel and heated to 68–70°C. While the reaction vessel was being heated, tissue culture polystyrene (TCPS) dishes (BD BioSciences, San Diego, CA, <http://www.bdbiosciences.com>) were activated by UVO treatment (Jetlight) for 40 minutes to create initiation sites on the

surface. After activation, the dishes were transferred to a reaction vessel and the temperature was increased to 76–80°C. Surface-initiated polymerization occurred over a 2.5 hour time period under argon atmosphere at 76–80°C. Once the process was complete, TCPS dishes and control samples were removed from the reaction vessel and rinsed in a 1% saline (w/v) solution at 50°C.

Matrigel (BD BioSciences) was diluted to a concentration of 100 µg/ml in cold DMEM/F12 (Gibco) and then applied to TCPS dishes or flasks (BD BioSciences). The coating was allowed to polymerize during 2 hours incubation at room temperature. Before plating cells, excess Matrigel-DMEM/F12 solution was aspirated, and the dishes were washed with sterilized Dulbecco's phosphate buffered saline (Gibco). Human Laminin-511 (Biolamina, Sundbyberg, Sweden, <http://www.biolamina.com>) was diluted to a concentration of 10 µg/ml in phosphate buffered saline (PBS; Gibco). Vitronectin (R&D Systems, Minneapolis, MN, <http://www.rndsystems.com>) was diluted to 5 µg/ml in PBS (Gibco). Coatings of Laminin or Vitronectin were applied to TCPS dishes following the manufacturer's protocols.

### Cell Culture of hPSCs

Unless otherwise specified, hESCs (H1, NIH registration # 0043 and H9, NIH registration number # 0062 from WiCell Research Institute, Madison, WI, <http://www.wicell.org>; and CHB10, NIH registration number 0009 from Children's Hospital Corporation, Boston, MA) and hiPSCs derived in our lab [24] from human gingival fibroblasts and foreskin fibroblasts (hGF2-iPSCs, hGF4-iPSCs and hFF-iPSCs) were cultured on PMEDSAH, Matrigel, human Laminin-511, Vitronectin, and MEFs with hPSC culture medium (human-cell-conditioned medium (HCCM, MTI-GlobalStem) supplemented with 5 ng/ml of human recombinant basic fibroblast growth factor (bFGF; Invitrogen, Carlsbad, CA, <http://www.invitrogen.com>), and 1% antibiotic-antimycotic (Gibco). The hPSC culture medium was replaced every other day. Differentiated cells were mechanically removed with a sterile pulled-glass pipet under a stereomicroscope (LeicaM29.5, Leica Microsystems, Buffalo Grove, IL, <http://www.leicamicrosystems.com>). Undifferentiated colonies were cut and passed as small cell clusters for three passages for each culture condition before analysis.

### MEF-Conditioned Medium Preparation and Extracellular Matrix Deposition

Twenty-four hours after plating irradiated MEFs at a density of  $2 \times 10^4$  cells per cm<sup>2</sup> on gelatin-coated tissue culture dishes, fibroblast culture medium was replaced with hPSC culture medium, and collected the following day, and was labeled as MEF1-CM (conditioned medium). Then, hPSC culture medium was replaced every other day, and CM was collected again after 6 days (MEF7-CM). MEF-CM were stored at –20°C before being used in hPSC culture. MEF-ECM (extracellular matrix) deposits were prepared as described previously [22]. Briefly, irradiated MEFs were cultured as described above and during the same period of time. At the time of isolating the ECM deposits, MEFs were washed twice with PBS and then lysed in buffer containing 0.5% (v/v) of Triton X-100/PBS and 0.035 ml of ammonium hydroxide solution (NH<sub>4</sub>OH) per 100 ml for 5 minutes at room temperature. Plates with ECM deposited were washed three times with PBS before being used in cell culture.

### RNA Isolation and Quantitative Reverse Transcriptase Polymerase Chain Reaction

RNA was isolated and purified with the RNA easy Mini-Kit (Qiagen, Hilden, Germany, <http://www1.qiagen.com>) following the manufacturer's protocol. RNA quality and concentration was measured with a Synergy NEO HTS Multi-Mode Microplate Reader (BioTek Instruments, Winooski, VT, <http://www.biotek.com>). Reverse transcription from 1  $\mu$ g of total RNA into cDNA was done using SuperScript III First-Strand Synthesis SuperMix (Invitrogen). Quantitative polymerase chain reaction (PCR) was performed by TaqMan probes (Applied Biosystems, Foster City, CA, <http://www.appliedbiosystems.com>) and TaqMan Universal PCR Master Mix (Applied Biosystems) on 7900 HT Fast Real Time PCR system (Applied Biosystems). Gene expression data were normalized to the expression levels of GAPDH and calculated by the  $\Delta\Delta C_T$  expression level.

### Western Blot Analysis

The following antibodies were used: OCT4 antibody (1:2,000; Cat. 4286, Cell Signaling Technology, Beverly, MA, <http://www.cellsignal.com>), SOX2 antibody (1:1,000; Cat. 2748, Cell Signaling Technology), KLF4 antibody (1:1,000; Cat. 12173, Cell Signaling Technology), C-MYC antibody (1:1,000; Cat. 9402, Cell Signaling Technology), NANOG antibody (1:1,000; Cat. 3580, Cell Signaling Technology), DPPA5 antibody (2  $\mu$ g/ml; Cat. MAB3984, R&D systems), DDK antibody (1: 2,000, Cat. TA50011, OriGene, Rockville, MD, <http://www.origene.com>),  $\alpha$ -tubulin antibody (1:3,000; Cat. sc-8035, Santa Cruz Biotechnology, Santa Cruz, CA, <http://www.scbt.com>), and  $\beta$ -actin antibody (1:1,000; Cat. 4970, Cell Signaling Technology). Whole cell lysates were prepared from cells, separated on 10% SDS-polyacrylamide gel, and transferred to polyvinylidene difluoride membranes. The membranes were incubated with 5% milk in TBST (w/v) for 0.5 hour and then incubated with primary antibodies overnight at 4°C. Blots were incubated with horseradish peroxidase-coupled secondary antibodies (Promega, Madison, WI, <http://www.promega.com>; R&D systems) for 1 hour, and protein expression was detected with SuperSignal West Pico Chemiluminescent Substrate or SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific, Waltham, MA, <http://www.thermofisher.com>). ImageJ software (<http://rsb.nih.gov/ij>) was used for quantification of Western blots.

### Directed Cell-Lineage Differentiation and Embryoid Body Formation

Embryoid body (EB) formation was achieved by culturing clusters of hPSCs in suspension with DMEM (Gibco) supplemented with 10% FBS for 10 days. Directed cell-lineage differentiation was performed on Matrigel coated dishes using the following protocols [25]. hPSCs were induced to differentiate in chemically defined medium (CDM) base consisting of DMEM/F12 (Gibco) supplemented with  $1 \times N2$  (Invitrogen),  $1 \times B27$  (Invitrogen), 0.11 mM 2-mercaptoethanol, 1 mM non-essential amino acids, 2 mM L-glutamine, and 0.5 mg/ml BSA (fraction V; Sigma-Aldrich). To induce definitive endoderm (pancreatic differentiation), 100 ng/ml human recombinant activin A (Stemgent, Lexington, MA, <http://www.stemgent.com>) was added to CDM, and cells were then cultured in this condition for 6 days, followed by culture in CDM without

activin A for another 9 days. For mesoderm (cardiomyocyte differentiation), cells were cultured in CDM supplemented with 50 ng/ml human recombinant bone morphogenetic protein (BMP) 4 (Stemgent) and 50 ng/ml human recombinant activin A (Stemgent) for 4 days, then further cultured in CDM without activin A and BMP4 for an additional 10 days. For ectoderm (neuronal differentiation), 100 ng/ml human recombinant Noggin (Stemgent) was added to the CDM, and cells were cultured for 8 days. In addition, to test the impact of DPPA5 on hPSCs differentiation, neuroectoderm differentiation was induced as previously described [17]. Briefly, hESCs were grown in chemical defined medium with 10  $\mu$ M SB431542 (Sigma-Aldrich) and 12 ng/ml bFGF (Invitrogen) for 7 days.

### Retrovirus Production and Transduction into Cells


Retrovirus ( $10 \times$ ) was produced with the plasmids *pMXs-hOCT3/4*, *pMXs-hSOX2*, *pMXs-hKLF4*, *pMXs-hC-MYC*, *pMXs-DPPA5*, and *pMXs-GW* (as control) (Addgene plasmids #: 17217, 17218, 17219, 17220, 13352, and 18656, respectively); by the University of Michigan Vector Core using standard protocols.

### DPPA5 Overexpression

Single hPSCs ( $2 \times 10^4$ ) were plated on a Matrigel-coated 60 mm TCPS dishes in hPSC culture medium supplemented with 10  $\mu$ M of Rho-associated coiled coil forming protein serine/threonine kinase (ROCK) inhibitor (Sigma-Aldrich) and infected with *DPPA5* retroviruses. Fibroblasts ( $1.5 \times 10^5$ ) were plated on a 35 mm TCPS dishes in fibroblast culture medium and infected by  $1 \times DPPA5$  retroviruses plus polybrene (10  $\mu$ g/ml; Sigma-Aldrich) when cell confluence reached about 60%. In addition, fibroblasts were also transfected in a 35 mm TCPS dish with 2  $\mu$ g pCMV6-Entry plasmid containing *DPPA5* human cDNA ORF Clone (Cat. RC222509, OriGene) using FuGENE 6 transfection reagent (Promega). The construct pCMV6-Entry (OriGene) was used as a control. DDK-tagged *DPPA5* plasmid (Cat. RC222509, OriGene) was transfected into hESCs using a modified-reversed transfection protocol [26]. Briefly, 2  $\mu$ g of DDK-tagged *DPP5* plasmid-FuGENE 6 complex were mixed with Matrigel during the 2 hour polymerization period. Single hESCs were then seeded on Matrigel-plasmid coated dishes, and cell culture medium was replaced the following day.

### Coimmunoprecipitation

Immunoprecipitation (IP) was performed using the ImmunoCruz IP/WB Optima C System (Santa Cruz Biotechnology) following the manufacturer's protocol. Briefly, hESCs protein extracts were prepared in CHAPS lysis and IP buffer (FIVEphoton Biochemicals, San Diego, CA, <http://www.fivephoton.com>) with protease inhibitor (FIVEphoton Biochemicals) and phosphatase inhibitor (FIVEphoton Biochemicals). hESC lysate (700  $\mu$ g of total protein) was precleared with Preclearing Matrix C-mouse (Santa Cruz Biotechnology) for 1.5 hours at 4°C on a rotator. Meanwhile, NANOG antibody (Cat. ab62734, Abcam, Cambridge, U.K., <http://www.abcam.com>), DDK antibody (Cat. TA50011, OriGene), OCT4 antibody (Cat. 4286, Cell Signaling), SOX2 antibody (Cat. 2748, Cell Signaling), normal mouse IgG (Santa Cruz Biotechnology) or normal rabbit IgG (Santa Cruz Biotechnology) were mixed and incubated to form IP antibody-IP matrix complex and the control-IP matrix complex, respectively. After 1 hour of incubation at 4°C on a rotator, IP



**Figure 1.** Differences in *DPPA5* gene expression and protein levels in human pluripotent stem cells (hPSCs) cultured on irradiated MEFs and feeder-free substrates. **(A):** Relative transcript levels of *DPPA5* were higher in human embryonic stem cells (hESCs) (H9) cultured on PMEDSAH compared to that on MEFs, while relative transcript levels of *OCT4*, *SOX2*, *KLF4*, *C-MYC*, and *NANOG* showed no significant differences in expression. **(B):** Relative transcript levels of *DPPA5* were higher in multiple types of hPSCs (H9, CHB10, hFF-iPSCs, hGF2-iPSCs, and hGF4-iPSCs) cultured on PMEDSAH compared to MEFs. **(C):** Western blot analysis and relative signal intensity of *DPPA5*, *NANOG*, *OCT4*, *SOX2*, *KLF4*, and *C-MYC* proteins in hESCs cultured on MEFs and PMEDSAH.  $\alpha$ -Tubulin was used as a loading control. **(D):** Compared to when cultured on MEFs, the relative transcript levels of *DPPA5* were higher in hESCs (CHB10) cultured on feeder-free substrates such as PMEDSAH, Matrigel, Laminin, and Vitronectin. Plot data presented as mean  $\pm$  SD from three independent experiments (\*,  $p < .05$ ). Abbreviations: *DPPA5*, developmental pluripotency associated 5; hGF, human gingival fibroblasts; hFF, human foreskin fibroblasts; iPSCs, induced pluripotent stem cells; MEFs, mouse embryonic fibroblasts; PMEDSAH, poly[2-(methacryloyloxy) ethyl dimethyl-(3-sulfopropyl) ammonium hydroxide].

antibody-IP matrix complex was washed with PBS (Gibco). The supernatant was discarded after centrifugation. The precleared hPSCs lysate supernatant was transferred to the pelleted IP antibody-IP matrix complex and incubated at 4°C on a rotator for 4 hours. After incubation and centrifugation, pelleted matrix was washed with PBS, and Western blot analysis was performed to detect the interaction between *DPPA5* and *NANOG*, *OCT4* or *SOX2*. Whole hPSCs lysate was used as input.

### Protein Stability Assay

hPSCs were infected with *DPPA5* or control (pMXs-GW) retroviruses. After 72 hours, cycloheximide (CHX; Sigma-Aldrich) was added to the culture medium at a concentration of 45  $\mu$ g/ml. CHX treatment lasted until cells were harvested at different time points (0.5 hours, 1 hours, 1.5 hours after CHX addition). Equal amounts of protein were loaded from each treated sample and analyzed by Western blot assays.


### Immunofluorescence staining

Cells were fixed in 4% paraformaldehyde for 30 minutes at room temperature and then permeabilized with 0.1% Triton

X-100 for 10 minutes. Primary antibodies against *DPPA5* (Cat. MAB3984, R&D systems), *NANOG* (Cat. ab62734, Abcam), *SSEA4* (Cat. sc-21704, Santa Cruz Biotechnology), *OCT4* (Cat. sc-8629, Santa Cruz Biotechnology), *SOX2* (ab5603, Millipore, Billerica, MA, <http://www.millipore.com>), *TRA-1-81* (Cat. mab4381, Millipore), *SSEA3* (Cat. mab4303, Millipore), *TRA-1-60* (Cat. sc-21705, Santa Cruz Biotechnology) were diluted in 1% normal serum (v/v) and incubated overnight at 4°C and detected with respective secondary antibodies. Sample images were captured using a Nikon TE2000-S inverted microscope with a Nikon DS-Ri1 camera or using Nikon confocal microscope system A1<sup>+</sup>.

### Derivation of hiPSCs and Quantification of Reprogramming Efficiency

For iPSC reprogramming,  $1.5 \times 10^5$  human gingival fibroblasts were plated on 35 mm TCPS dishes in fibroblast culture medium. When cell confluence reached about 60%, cells were infected by retroviruses (*KLF4*, *C-MYC*, *OCT4*, and *SOX2*; *KMOS*) using the method described above. In experimental groups, fibroblasts were also infected with retroviruses



**Figure 2.** Soluble factors and ECM secreted by irradiated MEFs inhibited *DPPA5* expression in human pluripotent stem cells (hPSCs) compared to feeder-free conditions. The control culture condition was PMEDSAH (substrate) plus HCCM (medium). **(A):** Relative transcript levels of *DPPA5* in hESCs cultured in control culture condition, PMEDSAH plus day 1 MEF-CM, and PMEDSAH plus day 7 MEF-CM. **(B):** Relative transcript levels of *DPPA5* in hESCs cultured in control culture condition, day 1 MEF-ECM plus HCCM, and day 7 MEF-ECM plus HCCM. *OCT4* gene expression was used as a marker indicating the undifferentiated state of the collected hESCs. Data presented as mean  $\pm$  SD from three independent experiments (\*,  $P < .05$ ). Abbreviations: CM, conditioned media; DPPA5, developmental pluripotency associated 5; ECM, extracellular matrix; HCCM, human-cell-conditioned medium; MEF, mouse embryonic fibroblast; PMEDSAH, poly[2-(methacryloyloxy) ethyl dimethyl-(3-sulfopropyl) ammonium hydroxide].

carrying *DPPA5* on day 0, day 6, day 9, and day 12, respectively. Three days after KMOS infection, cells were trypsinized and passed to Matrigel-coated or MEF-plated flasks (75 cm<sup>2</sup>). At that time, the fibroblast culture medium was replaced by hPSC culture medium supplemented with 10  $\mu$ M of ROCK inhibitor (Sigma-Aldrich). The hPSC culture medium with ROCK inhibitor was refreshed every day until day 23, when cells were either analyzed by alkaline phosphatase (AP) activity or submitted for flow cytometry analysis. AP activity and colony morphology (well defined borders and high nuclei per cytoplasmic ratio) were used to identify reprogrammed hiPSC colonies (Supporting Information Fig. S3C, S3D). The number of hiPSC colonies in control and experimental groups were quantified and used to calculate the reprogramming efficiency as follows: the number of hiPSC colonies in each group was divided by  $1.5 \times 10^5$ , which was the original number of fibroblasts plated for each group before reprogramming.

#### Alkaline Phosphatase Staining

AP staining was done with the Alkaline Phosphatase Staining Kit (Stemgent). Cells were fixed with fixing solution for 2–5 minutes, then rinsed and incubated in AP Substrate Solution in the dark at room temperature for 15 minutes. Cells were rinsed and covered with  $1 \times$  PBS to prevent drying before quantitative analysis.

#### Flow Cytometry Analysis

Cells were washed with PBS and harvested by incubation in 0.25% trypsin-EDTA (Gibco). After trypsinization, the cells were incubated first with human IgG to block nonspecific binding and then with SSEA-4 phycoerythrin (PE)-conjugated antibody (Cat. FAB1435p, R&D systems) or mouse anti-human

TRA-1-60 PE-conjugated antibody (Cat. 560193, BD Pharmingen, San Diego, CA, <http://wwwbdbiosciences.com>) and then analyzed by flow cytometry. Analysis was carried out with MoFlo Astrios (Beckman Coulter, Brea, CA, <http://www.beckmancoulter.com>) using standard procedures. Background fluorescence and autofluorescence were determined using cells incubated with Mouse IgG1 PE isotype control (Cat. 1c002p, R&D systems).

#### Statistical Analysis

At least three independent replicates of each experiment were performed. Two data sets were compared using the Student's *t* test function in Excel (Microsoft, Seattle, WA) to calculate *p* values. Multiple data sets were compared using one-way ANOVA analysis followed by the Tukey's post hoc test to calculate *p* values. Level of statistical significance was set at  $p < .05$ .


## RESULTS

### DPPA5 Expression in hPSCs is Higher when Cultured on Feeder-Free Substrates than on MEFs

To investigate the mechanism by which synthetic substrates such as PMEDSAH support hPSC self-renewal in feeder-free conditions, we compared the expression of pluripotency-related genes in H9 hESCs cultured on PMEDSAH versus MEFs after three consecutive passages. Quantitative RT-PCR analysis demonstrated that *DPPA5* gene expression levels were significantly higher in hESCs cultured on PMEDSAH compared to on MEFs, while the expression of other pluripotency-related factors such as *OCT4*, *SOX2*, *KLF4*, *C-MYC*, and *NANOG* was not significantly changed (Fig. 1A). Similar results were obtained with the CHB10 hESC line and three independent hiPSC lines

(Fig. 1B). Western blot analysis demonstrated that protein levels of DPPA5 and NANOG were higher in hPSCs cultured on PMEDSAH compared to MEFs, while other pluripotency-related factors showed no significant differences (Fig. 1C). The mRNA expression of *DPPA5* in hPSCs was then compared to cells cultured on MEFs and other feeder-free conditions

(Matrigel, Laminin-511, and Vitronectin). Quantitative RT-PCR analysis demonstrated higher gene expression of *DPPA5* in hPSCs grown on feeder-free substrates compared to cells cultured on MEFs, while no significant mRNA expression differences were observed among hESCs cultured in these feeder-free conditions (Fig. 1D).




Previously, we demonstrated that both the ECM and soluble factors secreted by MEFs significantly impact the self-renewal of hESCs [22]. Therefore, we hypothesized that the ECM and soluble factors secreted by MEFs may inhibit *DPPA5* expression in hPSCs, compared to feeder-free conditions. MEF-CM and ECM deposits were prepared on TCPS dishes as described in the Materials and Methods section and used to culture hESCs for three passages. The combination of PMEDSAH and HCCM was set as the control culture condition. In addition, cells were cultured on PMEDSAH plus day 1 or day 7 MEF-CM and day 1 or day 7 MEF-ECM plus HCCM. The mRNA expression of *OCT4* was used as an indicator of the undifferentiated state of hESCs. Quantitative RT-PCR analysis demonstrated that, compared to the control condition, hPSCs expressed significantly lower levels of *DPPA5* in PMEDSAH with day 7 MEF-CM (Fig. 2A), indicating that soluble factors secreted by MEFs inhibit *DPPA5* expression. Similarly, compared to the control condition, the expression of *DPPA5* was significantly lower in hPSCs cultured on MEF-ECM plus HCCM (Fig. 2B), indicating that the ECM deposited by MEFs also inhibits *DPPA5* expression in hPSCs. Taken together, these data suggested that soluble factors and ECM deposited by irradiated MEFs inhibit *DPPA5* gene expression in hPSCs.

We analyzed *DPPA5* gene expression levels in hPSCs and their differentiated derivative cells. Quantitative RT-PCR demonstrated that *DPPA5* expression levels were significantly upregulated in iPSCs compared to their corresponding parental fibroblasts (Fig. 3A). Conversely, when compared to undifferentiated hESCs, *DPPA5* expression levels significantly decreased after EB formation (Fig. 3B) and in cells induced to endodermal, mesodermal, and ectodermal lineages (Fig. 3C). Cell lineage differentiation and EB formation was confirmed by increasing expression of factors representative of each germ layer (Supporting Information Fig. S1; Table S1).

Immunocytochemistry analysis demonstrated that DPPA5 and NANOG protein were observed in undifferentiated hESCs and decreased in differentiated cells (Supporting Information Fig. S2A, S2B). Our finding that *DPPA5* expression was higher in undifferentiated hPSCs compared to differentiated cells is consistent with other studies that used *DPPA5* as a PSC

**Figure 3.** Differences in *DPPA5* expression between undifferentiated and differentiated human pluripotent stem cells and somatic cells. **(A):** Relative transcript levels of *DPPA5* increased in iPSCs (hFF-iPSCs, hGF2-iPSCs, and hGF4-iPSCs) compared to corresponding parental fibroblasts. **(B):** Relative transcript levels of *OCT4*, *SOX2*, and *DPPA5* decreased after EB formation from hESCs. **(C):** Relative transcript levels of *DPPA5* decreased after directed cell lineage differentiation from hESCs into endodermal, mesodermal, and ectodermal derivatives. Data presented as mean  $\pm$  SD from three independent experiments (\*,  $p < .05$ ). Abbreviations: DPPA5, developmental pluripotency associated 5; EB, embryoid body; hESCs, human embryonic stem cells; hFF, human foreskin fibroblasts; hGF, human gingival fibroblasts; iPSCs, induced pluripotent stem cells.



**Figure 4.** Regulation of NANOG protein levels by DPPA5 in human pluripotent stem cells (hPSCs). **(A):** Relative transcript levels of *DPPA5*, *NANOG*, *OCT4*, *SOX2*, *KLF4*, and *C-MYC* between control fibroblasts and with *DPPA5* overexpression. **(B):** Western blot analysis and relative signal intensity of *DPPA5*, *NANOG*, *OCT4*, *SOX2*, *KLF4*, and *C-MYC* proteins between control fibroblasts and fibroblasts with *DPPA5* overexpression.  $\beta$ -Actin was used as a loading control. **(C):** Relative transcript levels of *DPPA5*, *NANOG*, *OCT4*, *SOX2*, *KLF4*, and *C-MYC* between control hESCs and hESCs with *DPPA5* overexpression. **(D):** Western blot analysis and relative signal intensity of *DPPA5*, *NANOG*, *OCT4*, *SOX2*, *KLF4*, and *C-MYC* proteins between control hESCs and hESCs with *DPPA5* overexpression.  $\beta$ -Actin was used as a loading control. Plot data are presented as mean  $\pm$  SD from three independent experiments (\*,  $p < .05$ ). Abbreviations: DPPA5, developmental pluripotency associated 5; hESCs, human embryonic stem cells.

marker [9, 12–14, 27–30]. This specific expression pattern suggested that DPPA5 might play an important role in hPSC self-renewal and pluripotency.

#### DPPA5 Regulates NANOG Protein Levels


The higher expression of DPPA5 in hPSCs cultured under feeder-free conditions compared to MEFs provoked our interest in elucidating the function of DPPA5. Overexpression of *DPPA5* in fibroblasts did not significantly affect gene expression of *OCT4*, *SOX2*, *KLF4*, *C-MYC*, and *NANOG* (Fig. 4A). However, in fibroblasts with overexpressed DPPA5, in addition to detecting a significant increase in DPPA5 protein levels, we also observed an increase in NANOG protein levels via Western blot analysis (Fig. 4B). No change in protein levels was detected for other pluripotency-related factors. The same pattern was observed when *DPPA5* was overexpressed in hESCs. NANOG protein levels dramatically increased without significant changes in gene expression (Fig. 4C, 4D). These

data indicated that DPPA5 functions as a positive regulator of NANOG protein at a post-transcriptional level.

#### DPPA5 Protein Interacts with and Stabilizes NANOG Protein

Next, we investigated the extent to which DPPA5 may affect NANOG protein levels in hPSCs. Immunofluorescence staining and confocal microscopy analysis illustrated that DPPA5 was localized in both the cytoplasm and nucleus of hESCs. In addition, DPPA5 colocalized with NANOG in the nucleus (Fig. 5A), indicating a potential interaction between these two proteins.

Co-immunoprecipitation was performed to determine the interaction between DPPA5 and NANOG in hESCs. Western blot analysis demonstrated that NANOG was successfully immunoprecipitated with a NANOG IP antibody-IP matrix complex (Fig. 5B). Concurrent with this finding, DPPA5 was strongly coprecipitated with NANOG (Fig. 5B). IP of DPPA5 was achieved by pulling-down DDK protein from hESCs




**Figure 5.** Protein interaction and stabilization between DPPA5 and NANOG in human pluripotent stem cells (hPSCs). **(A):** Representative confocal microscopy images of immune fluorescent staining of human embryonic stem cells (hESCs) with NANOG and DPPA5 primary antibodies. DAPI shows nuclear staining. The merged images indicate the colocalization of DPPA5 and NANOG in hESC nucleus. Scale bars = 5  $\mu$ m. **(B):** Co-IP of endogenous NANOG and DPPA5 in hESCs. hESCs extracts prepared in CHAPS lysis and IP buffer were immunoprecipitated with anti-NANOG or control IgG antibody. The immune complexes and the input (whole hESC lysate) were analyzed by Western blot with antibodies specific to NANOG or DPPA5. **(C):** Co-IP of DDK-DPPA5 and NANOG in hESCs. hESCs were transfected with DDK-tagged DPPA5 plasmid. hESC extracts prepared in CHAPS lysis and IP buffer were immunoprecipitated with anti-DDK or control IgG antibody. The immune complexes and the input (whole hESC lysate) were analyzed by Western blot with antibodies specific to DDK and NANOG. **(D):** The protein levels of NANOG and DPPA5 in control hESCs or hESCs with *DPPA5* overexpression were analyzed at the indicated time points after CHX (45  $\mu$ g/ml) treatment. Western blot analysis and relative signal intensity indicated that DPPA5 supports NANOG protein stability in hESCs.  $\beta$ -Actin was used as a loading control. Plot data is presented as mean  $\pm$  SD from three independent experiments (\*,  $p < .05$ ). Abbreviations: CHX, cycloheximide; DAPI, 4',6-diamidino-2-phenylindole; DPPA5, developmental pluripotency associated 5; IP, immunoprecipitation.

transfected with a DDK-tagged DPPA5 plasmid. NANOG was coprecipitated with DDK-tagged DPPA5 (Fig. 5C). These data indicated the interaction between DPPA5 and NANOG protein. No protein was coprecipitated by the normal mouse IgG-IP matrix complex, suggesting nonspecific binding did not play a role in these experiments. Furthermore, DPPA5 was not coprecipitated with OCT4 or SOX2 (Supporting Information Fig. S2C, S2D), which suggested the specificity of interaction between DPPA5 and NANOG proteins. Protein stability assays were then performed to determine the extent to which DPPA5 inhibits NANOG protein degradation in hESCs. Western blot analysis demonstrated that the degradation of NANOG was significantly delayed by *DPPA5* overexpression in the presence of cycloheximide (Fig. 5D). Taken together, these data indicated that DPPA5 interacts with NANOG and stabilizes NANOG in hPSCs.

### DPPA5 Enhances the Function of NANOG

NANOG increases the transcription of *SALL4* and represses the transcription of *GATA6* and *SOCS3* through binding to their proximal gene promoters [31–35]. To study the extent to which DPPA5 enhances the function of NANOG in hPSCs, we examined the expression of NANOG target genes (*SALL4*, *GATA6*, and *SOCS3*) in response to *DPPA5* overexpression. The overexpression of DPPA5 in hESCs is shown in Figure 4C, 4D. We found that gene expression of *SALL4* was increased, while *GATA6* and *SOCS3* were repressed after *DPPA5* overexpression (Fig. 6A). This evidence suggested that DPPA5 not only increased NANOG protein levels through post-translational stabilization but also facilitated the function of NANOG on its target genes.

To test the impact of DPPA5 on NANOG in hESC differentiation, we induced hPSC neuroectoderm differentiation in




**Figure 6.** DPPA5 enhances the function of NANOG in human pluripotent stem cells (hPSCs). **(A):** The expression of NANOG target genes regulated by DPPA5. Relative transcript level of *SALL4* was higher, while *GATA6* and *SOCS3* were lower in hESCs with *DPPA5* overexpression compared to the control hESCs. **(B):** hESC differentiation regulated by DPPA5. After induced neuroectoderm differentiation in hESCs, the expression levels of pluripotency markers such as *OCT4* and *SOX2* decreased, while neuroectoderm markers *SOX1* and *NEUROD1* increased in both control and *DPPA5* overexpressed cells. In neuroectoderm differentiated cells, the expression levels of *SOX1* and *NEUROD1* were lower in *DPPA5* overexpressed cells compared to controls. Data presented as mean  $\pm$  SD from three independent experiments (\*,  $p < .05$ ). Abbreviations: bFGF, basic fibroblast growth factor; DPPA5, developmental pluripotency associated 5; hESCs, human embryonic stem cells.

control and *DPPA5* overexpressed hESCs with the knowledge that overexpression of *NANOG* blocks neuroectoderm differentiation [17]. We observed that after induced neuroectoderm differentiation in hESCs, the expression levels of pluripotency markers such as *OCT4* and *SOX2* were decreased, while neuroectoderm markers *SOX1* and *NEUROD1* were increased in both control and *DPPA5* overexpressed cells (Fig. 6B). Interestingly, in neuroectoderm differentiated cells, the expression levels of *SOX1* and *NEUROD1* were lower in *DPPA5* overexpressed cells compared to controls (Fig. 6B). Taken together, these data indicated that *DPPA5* promotes the function of *NANOG*.

#### DPPA5 Increases hiPSC-Reprogramming Efficiency

Because of the stabilizing action of *DPPA5* on *NANOG* in hESCs and the critical role of *NANOG* in hPSCs self-renewal and in the generation of hiPSCs [3, 19], we investigated whether *DPPA5* could have a positive effect during reprogramming of fibroblasts into hiPSCs (Supporting Information Fig. S3A, S3B). *DPPA5* was

added to the *KLF4*, *C-MYC*, *OCT4*, *SOX2* (*KMOS*) reprogramming cocktail to determine its effect on reprogramming of fibroblast into hiPSCs. Retroviruses encoding the *KMOS* cocktail were used to infect fibroblasts in both control and experimental groups on day 0. Experimental groups were additionally infected with retroviruses encoding *DPPA5* on day 0, day 6, day 9, and day 12 (experimental group-d0+D, d6+D, d9+D and d12+D, respectively). On day 23, hiPSC colonies were classified as successfully reprogrammed, or as pre-iPSCs by the following criteria: reprogrammed colonies should have positive AP staining, well-defined borders and cells should have a high nucleus:cytoplasm ratio (Supporting Information Fig. S3C). Pre-iPSCs were identified by undefined borders even if exhibiting AP activity (Supporting Information Fig. S3D). We found that overexpression of *DPPA5* on day 6, day 9, day 12, but not day 0, significantly ( $p < .05$ ) enhanced the generation of hiPSC colonies compared to the control group (Fig. 7; Supporting Information Table S2). The reprogramming efficiency was increased



**Figure 7.** DPPA5 (Developmental Pluripotency Associated 5) overexpression has an additive effect in hiPSC reprogramming. Day 6, day 9, and day 12-DPPA5 added groups (d6+D, d9+D, d12+D) had higher iPSC colony number compared to control group and day 0-DPPA5 added group (d0+D). In control group (Con), fibroblasts were infected on day 0 with retroviruses encoding *KLF4*, *C-MYC*, *OCT4*, and *SOX2* (*KMOS*) while in experimental groups in addition to this cocktail of reprogramming factors, cells were also infected with retrovirus encoding *DPPA5* on day 0 (d0+D), day 6 (d6+D), day 9 (d9+D), and day 12 (d12+D). hiPSC colonies were identified by positive alkaline phosphatase staining and morphological characteristics of colonies, quantified and compared among groups. Plot data are presented as mean  $\pm$  SD from three independent experiments (\*,  $p < .05$ ). Abbreviation: hiPSC, human induced pluripotent stem cell.

from 0.023% to 0.076% between the control group and the d9+D group. In addition, flow cytometry analysis at day 23 confirmed that the percent of both TRA-1-60<sup>+</sup> cells and SSEA4<sup>+</sup> cells was higher in d6+D groups compared to controls without DPPA5 and in cells reprogrammed in feeder-free conditions compared to cells on feeder cells (Supporting Information Fig. S4).

The derived hiPSCs from both control and d6+D groups were characterized by immunostaining with markers for pluripotency (Supporting Information Fig. S3E, S3F) and analysis of representative genes of the three germ layers after EB formation (Supporting Information Tables S3, S4). Taken together, our results indicate that DPPA5 had an additive effect to the reprogramming cocktail of OCT4, SOX2, KLF4, and C-MYC by increasing hiPSC-reprogramming efficiency.

## DISCUSSION

The potential for successful therapeutic application of hPSCs and their derivatives will depend, in part, on the ability to develop clinically compliant strategies for large-scale production of therapeutically relevant cells [36–38]. The large-scale expansion of hPSCs has been limited by xenogenic components and poorly defined culture conditions that use feeder cells and other animal-based products to support hESC self-renewal [1, 39, 40]. To overcome these limitations, the use of feeder-free conditions with human recombinant proteins like Laminin and Vitronectin have been tested for long-term maintenance of hESCs [41, 42]. The combination of these

xenogeneic-free substrates and chemically defined media such as mTesR, E-8, and X-VIVO10 [41, 43–45] represents significant progress in the development of hPSC culture systems.

Moreover, synthetic substrates such as PMEDSAH [20, 21] have demonstrated great potential for large-scale propagation of hESCs [46]. Our data suggest that in MEF conditions, the synthesis of soluble factors and the deposition of undefined ECM proteins inhibit DPPA5 expression in hPSCs compared to feeder-free culture conditions. These findings are consistent with our previous report that showed the capacity of  $\gamma$ -irradiated MEFs to support hESC self-renewal is compromised over time due to changes in the secretion of soluble factors and ECM [22]. These data support the trend in the evolution of hPSC culture from feeder-cell dependence and ill-defined conditions, to feeder-free and defined microenvironments [47].

Pluripotency and self-renewal are maintained in PSCs by a network of interacting transcription factors, influenced by specific signaling pathways [48], and these interactions may be different depending on the in vitro culture conditions. Our data identifies DPPA5 as a new component in this regulatory network of pluripotency that is differentially expressed depending on the culture conditions. DPPA5 is highly expressed in feeder-free conditions (PMEDSAH, Matrigel, Laminin-511, and Vitronectin) compared to feeder-dependent conditions (MEFs), suggesting that DPPA5 may play a more important role in hPSC maintenance under feeder-free conditions. Our findings that the molecular mechanisms supporting hPSC pluripotency are different depending on the culture conditions, as well as species differences between human and mouse ESCs, may explain discrepancies with a previous finding of no significant impact on mouse ESC self-renewal when *DPPA5* was knocked-out and cells were cultured on MEFs [11].

The identification of a functionally significant role for DPPA5 in hPSC self-renewal may contribute to a better understanding of how feeder-free conditions support hPSC self-renewal. This is especially important since the use of hPSCs in regenerative medicine will likely be dependent on the use of xenogenic and feeder-free conditions. Our data indicate that in hPSCs, DPPA5 regulates NANOG protein stability and enhances its function on target genes, which may result in pro-pluripotency conditions that better support self-renewal. This new finding in the regulation of NANOG by DPPA5 is important because of the central role that this transcription factor plays in PSC regulatory networks. NANOG is a homeodomain protein that regulates the transcriptional levels of other genes, such as *SALL4*, *GATA6*, and *SOCS3* [31–35, 49]. Previous findings demonstrating that downregulation of NANOG in hESCs induces differentiation [6], while its overexpression prevents differentiation [16–18], suggest that sufficient levels of NANOG are critical for hPSC self-renewal. Our study suggests that DPPA5 plays an important role in supporting hPSC self-renewal by facilitating the protein levels of NANOG, a master transcriptional regulator for hPSC pluripotency. DPPA5 stabilizes NANOG protein levels and enhances the upregulatory effects of NANOG on *SALL4*, a transcription factor required for ESC pluripotency, and the downregulatory effects of NANOG on *GATA6*, and *SOCS3*, well-known NANOG target genes that function in early stages of differentiation [35, 50, 51].

Another novel and potentially important finding is the mechanism by which DPPA5 facilitates NANOG protein levels. Previous studies reported transcriptional regulation of *NANOG*

by other pluripotency-related factors such as OCT4, SOX2, and KLF4 [52, 53]. Meanwhile, DPPA5 has been reported to be an RNA binding protein because it contains a KH domain [8]. Interestingly, we found that NANOG protein levels increased after *DPPA5* overexpression without significant changes at *NANOG* mRNA levels. We also found that both mRNA and protein levels of other key pluripotent-related transcription factors (OCT4, SOX2, and KLF4) remained unchanged after *DPPA5* overexpression. These findings led us to raise the hypothesis that DPPA5 directly interacts with and stabilizes NANOG proteins, which is supported by the co-IP and protein stability results. In support of these findings, a previous study showed that DPPA5 does not bind to and regulate *NANOG* mRNA after an IP-microarray screening [15]. In addition, our findings of the post-translational regulation of NANOG are consistent with other studies showing that, like other pluripotency-related transcription factors such as OCT4, KLF4, and C-MYC, NANOG is also an unstable protein with a relatively short half-life in hPSCs. These transcription factors are degraded through ubiquitin-dependent proteolysis [54–58], while proteasome inhibitors are able to block NANOG protein degradation in hPSCs and extend its half-life [59]. Our finding that DPPA5 interacts with and stabilizes NANOG provides an additional mode of regulation of NANOG in hPSCs, suggesting that in addition to the broadly investigated transcriptional regulation of pluripotency-related transcription factors, post-translational regulation also plays a role in the hPSC pluripotency regulatory network. We also observed that DPPA5 protein, like NANOG and other pluripotency-related factors, is degraded in a rapid manner in hPSCs (Fig. 5D). Thus, this regulatory model not only supports the hypothesis that DPPA5 is able to regulate NANOG, but also furthers our understanding of the molecular mechanisms that define hPSC pluripotency on synthetic substrates.

Human iPSCs reprogrammed from adult somatic cells by the process of induced pluripotency holds great potential for disease modeling, drug screening, and cell replacement therapy [60]. We found that the addition of *DPPA5* at 6, 9, or 12 days after initial *OSKM* cocktail treatment increased the generation of hiPSCs by threefold compared to controls, or when *DPPA5* is overexpressed with *OSKM* on day 0. This observation suggests that *DPPA5* may have an optimal window for being overexpressed in cells to efficiently promote iPSC-reprogramming and may be related to the timing of NANOG expression in the reprogramming process [61]. The central role of NANOG in reprogramming of somatic cells into iPSCs [3, 19, 62, 63], combined with our finding that DPPA5 regulates NANOG protein levels, suggests that DPPA5 may promote hiPSC-generation efficiency by enhancing NANOG stability and its function. This new finding is also consistent with a recent study showing the benefit of sequential introduction of reprogramming factors [64] in which a sequential epithelial-to-mesenchymal transition followed by mesenchymal-to-epithelial transition mechanism optimizes reprogramming. Interestingly, we observed a significant ( $p < .05$ ) increase in the number of

cells expressing the pluripotent markers TRA-1-60 and SSEA4 in cells that were infected with DPPA5 at day 6 compared to controls when MEFs were used as a substrate compared to the Matrigel group. This is consistent with our conclusion that factors secreted by MEFs negatively affected the expression and function of DPPA5 and NANOG and may affect the reprogramming efficiency of hiPSCs as well. Taken together, our data suggest an additive effect of DPPA5 in hiPSC generation extends our knowledge of iPSC reprogramming, and may further advance current reprogramming protocols.

## CONCLUSION

We provide new molecular insight into the function of the PSC marker DPPA5 in hPSCs. We established a role for DPPA5 in hPSCs and identified new functions of DPPA5 in hPSC biology, NANOG regulation and iPSC reprogramming. In vitro culture conditions influence the expression of DPPA5 in hPSCs. The ECM deposited by irradiated MEFs, as well as secreted soluble factors, inhibit the expression of DPPA5 in hPSCs, while its expression and function is permissive under feeder-free conditions. DPPA5 stabilizes NANOG and enhances the function of NANOG, a key transcription factor for hPSC pluripotency, which results in support of hPSC self-renewal. Finally, *DPPA5* increases the reprogramming efficiency of somatic cells into human iPSCs when transduced with *OCT4*, *SOX2*, *KLF4*, and *C-MYC*. In conclusion, DPPA5 plays an important role in supporting hPSC self-renewal and reprogramming on synthetic substrates. Our findings advance our knowledge of hPSC biology and offer improvements to current protocols in hPSC maintenance and reprogramming, which may contribute to the future application of these cells in regenerative medicine.

## ACKNOWLEDGMENTS

We thank Dr. Joerg Lahann and his lab for their assistance in preparing PMEDSAH plates, Dr. Shinya Yamanaka for the gift of the plasmids (Addgene plasmid #: 17217, 17218, 17219, 17220, 13352, and 18656), and the National Institutes of Health (R01DE016530-08 to PHK) for support.

## AUTHOR CONTRIBUTIONS

X.Q. and P.H.K.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; J.K.K. and L.G.V.-D.: collection and/or assembly of data, data analysis and interpretation, and final approval of manuscript; W.T.: collection and/or assembly of data and final approval of manuscript.

## DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest.

## REFERENCES

- 1 Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. *Science* 1998;282:1145–1147.
- 2 Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007;131:861–872.
- 3 Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. *Science* 2007;318:1917–1920.

- 4 Hay DC, Sutherland L, Clark J et al. Oct4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. *STEM CELLS* 2004;22:225–235.
- 5 Boyer LA, Lee TI, Cole MF et al. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* 2005;122:947–956.
- 6 Hyslop L, Stojkovic M, Armstrong L et al. Downregulation of NANOG induces differentiation of human embryonic stem cells to extraembryonic lineages. *STEM CELLS* 2005;23:1035–1043.
- 7 Fong H, Hohenstein KA, Donovan PJ. Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. *Stem Cells* 2008;26:1931–1938.
- 8 Pierre A, Gautier M, Callebaut I et al. Atypical structure and phylogenomic evolution of the new eutherian oocyte- and embryo-expressed KHDC1/DPPA5/ECAT1/OOEP gene family. *Genomics* 2007;90:583–594.
- 9 Kim SK, Suh MR, Yoon HS et al. Identification of developmental pluripotency associated 5 expression in human pluripotent stem cells. *STEM CELLS* 2005;23:458–462.
- 10 Western P, Maldonado-Saldivia J, van den Bergen J et al. Analysis of Esg1 expression in pluripotent cells and the germline reveals similarities with Oct4 and Sox2 and differences between human pluripotent cell lines. *STEM CELLS* 2005;23:1436–1442.
- 11 Amano H, Itakura K, Maruyama M et al. Identification and targeted disruption of the mouse gene encoding ESG1 (PH34/ECAT2/DPPA5). *BMC Dev Biol* 2006;6:11.
- 12 Aoki T, Ohnishi H, Oda Y et al. Generation of induced pluripotent stem cells from human adipose-derived stem cells without c-MYC. *Tissue Eng Part A* 2010;16:2197–2206.
- 13 Mamidi MK, Pal R, Mori NA et al. Co-culture of mesenchymal-like stromal cells derived from human foreskin permits long term propagation and differentiation of human embryonic stem cells. *J Cell Biochem* 2011;112:1353–1363.
- 14 Zhang Y, Wei C, Zhang P et al. Efficient reprogramming of naive-like induced pluripotent stem cells from porcine adipose-derived stem cells with a feeder-independent and serum-free system. *PLoS One* 2014;9:e85089.
- 15 Tanaka TS, Lopez de Silanes I, Sharova LV et al. Esg1, expressed exclusively in preimplantation embryos, germline, and embryonic stem cells, is a putative RNA-binding protein with broad RNA targets. *Dev Growth Differ* 2006;48:381–390.
- 16 Wang Z, Oron E, Nelson B et al. Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. *Cell Stem Cell* 2012;10:440–454.
- 17 Vallier L, Mendjan S, Brown S et al. Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. *Development* 2009;136:1339–1349.
- 18 Suzuki A, Raya A, Kawakami Y et al. Nanog binds to Smad1 and blocks bone morphogenetic protein-induced differentiation of embryonic stem cells. *Proc Natl Acad Sci USA* 2006;103:10294–10299.
- 19 Hanna J, Saha K, Pando B et al. Direct cell reprogramming is a stochastic process amenable to acceleration. *Nature* 2009;462:595–601.
- 20 Villa-Diaz LG, Nandivada H, Ding J et al. Synthetic polymer coatings for long-term growth of human embryonic stem cells. *Nat Biotechnol* 2010;28:581–583.
- 21 Nandivada H, Villa-Diaz LG, O’Shea KS et al. Fabrication of synthetic polymer coatings and their use in feeder-free culture of human embryonic stem cells. *Nat Protoc* 2011;6:1037–1043.
- 22 Villa-Diaz LG, Pacut C, Slawny NA et al. Analysis of the factors that limit the ability of feeder cells to maintain the undifferentiated state of human embryonic stem cells. *STEM CELLS DEV* 2009;18:641–651.
- 23 Qian X, Villa-Diaz LG, Kumar R et al. Enhancement of the propagation of human embryonic stem cells by modifications in the gel architecture of PMEDSAH polymer coatings. *Biomaterials* 2014;35:9581–9590.
- 24 Villa-Diaz LG, Kim JK, Lahann J et al. Derivation and long-term culture of transgene-free human induced pluripotent stem cells on synthetic substrates. *STEM CELLS TRANSL MED* 2014;3:1410–1417.
- 25 Yao S, Chen S, Clark J et al. Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. *Proc Natl Acad Sci USA* 2006;103:6907–6912.
- 26 Villa-Diaz LG, Garcia-Perez JL, Krebsbach PH. Enhanced transfection efficiency of human embryonic stem cells by the incorporation of DNA liposomes in extracellular matrix. *STEM CELLS DEV* 2010;19:1949–1957.
- 27 Adjaye J, Huntriss J, Herwig R et al. Primary differentiation in the human blastocyst: Comparative molecular portraits of inner cell mass and trophectoderm cells. *STEM CELLS* 2005;23:1514–1525.
- 28 Xue F, Ma Y, Chen YE et al. Recombinant rabbit leukemia inhibitory factor and rabbit embryonic fibroblasts support the derivation and maintenance of rabbit embryonic stem cells. *Cell Reprogram* 2012;14:364–376.
- 29 Kues WA, Herrmann D, Barg-Kues B et al. Derivation and characterization of sleeping beauty transposon-mediated porcine induced pluripotent stem cells. *STEM CELLS DEV* 2013;22:124–135.
- 30 Koh S, Thomas R, Tsai S et al. Growth requirements and chromosomal instability of induced pluripotent stem cells generated from adult canine fibroblasts. *STEM CELLS DEV* 2013;22:951–963.
- 31 Frankenberg S, Gerbe F, Bessonard S et al. Primitive endoderm differentiates via a three-step mechanism involving Nanog and RTK signaling. *Dev Cell* 2011;21:1005–1013.
- 32 Singh AM, Hamazaki T, Hankowski KE et al. A heterogeneous expression pattern for Nanog in embryonic stem cells. *STEM CELLS* 2007;25:2534–2542.
- 33 Marson A, Levine SS, Cole MF et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. *Cell* 2008;134:521–533.
- 34 Stuart HT, van Oosten AL, Radziszewska A et al. NANOG amplifies STAT3 activation and they synergistically induce the naive pluripotent program. *Curr Biol* 2014;24:340–346.
- 35 Lim CY, Tam W, Zhang et al. Sall4 regulates distinct transcription circuitries in different blastocyst-derived stem cell lineages. *Cell Stem Cell* 2008; 3:543–54.
- 36 McCall MD, Toso C, Baetge EE et al. Are stem cells a cure for diabetes? *Clin Sci* 2010; 118:87–97.
- 37 Dominguez-Bendala J, Inverardi L, Ricordi C. Stem cell-derived islet cells for transplantation. *Curr Opin Organ Transplant* 2011;16:76–82.
- 38 Laflamme MA, Chen KY, Naumova AV et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. *Nat Biotechnol* 2007;25:1015–1024.
- 39 Richards M, Tan S, Fong CY et al. Comparative evaluation of various human feeders for prolonged undifferentiated growth of human embryonic stem cells. *STEM CELLS* 2003; 21:546–556.
- 40 Xu C, Inokuma MS, Denham J et al. Feeder-free growth of undifferentiated human embryonic stem cells. *Nat Biotechnol* 2001;19:971–974.
- 41 Braam SR, Zeinstra L, Litjens S et al. Recombinant vitronectin is a functionally defined substrate that supports human embryonic stem cell self-renewal via alpha-beta5 integrin. *STEM CELLS* 2008;26:2257–2265.
- 42 Miyazaki T, Futaki S, Hasegawa K et al. Recombinant human laminin isoforms can support the undifferentiated growth of human embryonic stem cells. *Biochem Biophys Res Commun* 2008;375:27–32.
- 43 Nagaoka M, Si-Tayeb K, Akaike T et al. Culture of human pluripotent stem cells using completely defined conditions on a recombinant E-cadherin substratum. *BMC Dev Biol* 2010;10:60.
- 44 Chen G, Gulbranson DR, Hou Z et al. Chemically defined conditions for human iPSC derivation and culture. *Nat Methods* 2011;8:424–429.
- 45 Li Y, Powell S, Brunette E et al. Expansion of human embryonic stem cells in defined serum-free medium devoid of animal-derived products. *Biotechnol Bioeng* 2005;91:688–698.
- 46 Qian X, Villa-Diaz LG, Krebsbach PH. Advances in culture and manipulation of human pluripotent stem cells. *J Dent Res* 2013;92:956–962.
- 47 Villa-Diaz LG, Ross AM, Lahann J et al. Concise review: The evolution of human pluripotent stem cell culture: From feeder cells to synthetic coatings. *STEM CELLS* 2013;31:1–7.
- 48 Ng HH, Surani MA. The transcriptional and signalling networks of pluripotency. *Nat Cell Biol* 2011;13:490–496.
- 49 Jauch R, Ng CK, Saikatendu KS et al. Crystal structure and DNA binding of the homeodomain of the stem cell transcription factor Nanog. *J Mol Biol* 2008;376:758–770.
- 50 Nagy A, Vintersten K. Murine embryonic stem cells. *Methods Enzymol* 2006;418:3–21.
- 51 Chambers I, Smith A. Self-renewal of teratocarcinoma and embryonic stem cells. *Oncogene* 2004;23:7150–7160.
- 52 Rodda DJ, Chew JL, Lim LH et al. Transcriptional regulation of nanog by OCT4 and SOX2. *J Biol Chem* 2005;280:24731–24737.
- 53 Chan KK, Zhang J, Chia NY et al. KLF4 and PBX1 directly regulate NANOG

expression in human embryonic stem cells. *STEM CELLS* 2009;27:2114–2125.

- 54** Chen ZY, Wang X, Zhou Y et al. Destabilization of Kruppel-like factor 4 protein in response to serum stimulation involves the ubiquitin-proteasome pathway. *Cancer Res* 2005;65:10394–10400.
- 55** Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: Stabilization of c-Myc in Burkitt's lymphoma cells. *Mol Cell Biol* 2000;20:2423–2435.
- 56** Moretto-Zita M, Jin H, Shen Z et al. Phosphorylation stabilizes Nanog by promoting its interaction with Pin1. *Proc Natl Acad Sci USA* 2010;107:13312–13317.
- 57** Liao B, Jin Y. Wwp2 mediates Oct4 ubiquitination and its own auto-ubiquitination in a dosage-dependent manner. *Cell Res* 2010;20:332–344.
- 58** Xu H, Wang W, Li C et al. WWP2 promotes degradation of transcription factor OCT4 in human embryonic stem cells. *Cell Res* 2009;19:561–573.
- 59** Ramakrishna S, Suresh B, Lim KH et al. PEST motif sequence regulating human NANOG for proteasomal degradation. *STEM CELLS DEV* 2011;20:1511–1519.
- 60** Ebben JD, Zorniak M, Clark PA et al. Introduction to induced pluripotent stem cells: Advancing the potential for personalized medicine. *World Neurosurg* 2011;76:270–275.
- 61** Plath K, Lowry WE. Progress in understanding reprogramming to the induced pluripotent state. *Nat Rev Genet* 2011; 12:253–265.
- 62** Liao J, Wu Z, Wang Y et al. Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factors. *Cell Res* 2008;18:600–603.
- 63** Silva J, Nichols J, Theunissen TW et al. Nanog is the gateway to the pluripotent ground state. *Cell* 2009;138:722–737.
- 64** Liu X, Sun H, Qi J et al. Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT-MET mechanism for optimal reprogramming. *Nat Cell Biol* 2013;15:829–838.



See [www.StemCells.com](http://www.StemCells.com) for supporting information available online.